μΜ for 48h with all treatments being refreshed after 24h) was shown to be (i) most efficient in exerting an anti-cancer effect when compared to higher concentrations (5-100 μΜ for 24 or 48h added as a single bolus) and (ii) specific to A375 cells while A431 and HaCaT cells remained unaffected. Such effect involved the activation of several caspases including (iii) initiator caspases 8, 9, 4 (indicating the involvement of intrinsic, extrinsic and endoplasmic reticulum-based pathways) and (iv) effector caspases 3, 7 and 6.
Conclusions: Utilization of low isothiocyanate concentrations (under conditions described herein) exerts an anti-cancer effect specific to human malignant melanoma cells and thus providing a therapeutic basis for their utilization in management of the disease.
Malignant melanoma is the fifth most common cancer in UK with its incidence rates being continuously rising faster than any other malignancy (1) . Epidemiological studies suggest that an increased dietary consumption of cruciferous vegetables can reduce cancer incidence. These effects can be attributed to the high levels of glucosinolates (GSLs) present which are sulphur-containing glycosides and precursors for a group of compounds called isothiocyanates (ITCs) (2) . Briefly, upon mechanical disruption of the plant cell wall (e.g. by chewing), the enzyme myrosinase is released which then catalyses the hydrolysis of GSLs to ITCs, with subsequent release of HSO4and D-glucose (3). Different GSLs can form different ITCs, since glucoraphanin acts as the precursor for sulforaphane (SFN), gluconasturtin for phenethyl isothiocyanate (PEITC) and glucotropaeolin for benzyl isothiocyanate (BITC) (4) .
There is much speculation as to how ITCs may exhibit their chemotherapeutic effects, but the likelihood is that multiple molecular events are responsible. Potential biochemical mechanisms include (i) inhibition of carcinogen activity via suppression of phase I enzymes in xenobiotic metabolism, (ii) stimulation of phase II enzymes and (ii) induction of apoptosis (5, 6) . Despite many reports demonstrating ITCs' effectiveness against different cancers there have been a limited number of studies investigating their ability to induce apoptosis in human malignant melanoma cells (7) which their results are dependent on the utilization of high concentrations of ITCs.
In this study, we have aim to develop a novel experimental in vitro model based on Public Health England, UK). All cell lines were cultured in DMEM medium (10% FBS, 2mM L-Glutamine and 1% Penicillin/Streptomycin) and maintained in a humidified atmosphere at 37 o C and 5% CO2. SFN, PEITC, BITC or vehicle were added either as (i) a single bolus concentration ranging between 5-100 μΜ for 24 to 48h or (ii) at 0.1-5 μΜ for 48h with all treatments being refreshed after 24h.
Cell viability assay. Cells (5x10 3 ) were seeded in 100 μl of complete medium into 96-well plates and kept overnight in the incubator before they were treated with either one of the treatment protocols. Cell viability was assessed by using the Alamar blue assay where in brief, resazurin sodium salt was dissolved in PBS (1mg/ml final concentration) and 10 μl of reagent were added into each well of the 96-well plates. After 4h of incubation, fluorescence intensity was measured at 560Exc/590Em nm by using a Spectramax M5 multi-mode plate reader (Sunnyvale, CA, USA). More specifically, SFN decreased cell viability at 10 μM onwards (24-48h) in A375 ( Figure   1A ) and HaCaT ( Figure 1D ) cells. PEITC also decreased cell viability levels but at a concentration of 25 μM onwards (24-48h) for A375 ( Figure 1B (Figure 2A and 2B respectively). However, at this concentration, cells exposed to SFN showed a more profound inhibitory effect on viability levels compared to PEITC (approximately 60% vs.
80% respectively). Finally, treatment with BITC also, statistically significantly decreased (P<0.05) the viability levels at concentrations as low as 2.5 μΜ onwards in A375 and A431 cells only. However, this effect was more profound in A375 cells where a 2.5 μΜ inhibition of cell viability was recorded to levels of ~70% which was further decreased to ~ 30% after treatment with 5 μM of BITC ( Figure 2C ).
Finally, in order to investigate whether treatment with ITCs induces an apoptotic response in A375 cells, the activity levels of the initiator caspases 4, 8 and 9 were evaluated. Activation of these caspases is indicative of the involvement of various apoptotic pathways in a manner where caspase 8 involves the extrinsic (29), caspase 9 the intrinsic (30) and caspase 4 the endoplasmic reticulum (ER)-dependent (31) pathways. Our data showed that treatment with BITC statistically significantly increased (P<0.05) the activity levels of all initiator caspases whereas this was the case only for caspase 9 in PEITC treated cells. Alternatively, treatment with SFN showed no statistically significant changes in the activity levels of any of the above-mentioned caspases ( Figure 3A-C) . Similarly, western blot analysis data indicate that each of the SFN, PEITC and BITC were responsible for inducing a statistically significant decrease (P<0.05) in protein expression levels of the effector procaspases 3 ( Figure 3D ) and 6 ( Figure 3E ) while for procaspase 7 this was the case only for BITC treatment ( Figure 3F ). Consequently, when these procaspases become activated they cleave specific cellular proteins including poly(ADP-ribose) polymerase (PARP) ( Figure 3D ) and lamins A and C ( Figure 3E ) such as in the case of procaspase 3 and 6, respectively. Overall, our results demonstrate that ITCs induce caspase activation in a manner which treatment with BITC results in the largest decrease in procaspase levels, followed by PEITC and SFN.
Discussion
The majority of various studies have utilized non-melanoma (8) (9) (10) (11) (12) (13) (14) and melanoma (15) (16) (17) (18) (19) experimental models based on a single bolus addition of large ITC concentrations where a wide range of biological effects were documented but without provision of appropriate control (non-tumorigenic) cells. Similarly, we have been able to document such anti-cancer activity in melanoma cells but also in control keratinocyte cells suggesting a nonspecific potency towards any type of cell line (tumorigenic or not). 
